PROSTATE CANCER DIAGNOSTICS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-167276 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Prostate Cancer Diagnostics Market

1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET
7.1 GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Abbott Laboratories
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Bayer Aktiengesellschaft
16.3 Danaher Corporation
16.4 Becton, Dickinson and Company
16.5 Foundation Medicine, Inc..
16.6 Cancer Genetics, Inc..
16.7 AstraZeneca.
16.8 Myriad Genetics Inc.
16.9 Agilent Technologies
16.10 Biocept, Inc.
16.11 Opko Health, Inc
16.12 Mdxhealth
16.13 3D Signatures,inc.
16.14 Genomic Health
16.15 Siemens Healthcare Gmbh
16.16 Diasorin S.p.a
16.17 Biomerieux SA
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Test TypePSA Tests
CTC Tests
Immunohistochemistry
PCA3 test
By End User
Hospital Associated Labs
Independent Diagnostic Laboratories
Cancer Research Institutes
Companies
Abbott Laboratories
Bayer Aktiengesellschaft
Danaher Corporation
Becton, Dickinson and Company
Foundation Medicine, Inc..
Cancer Genetics, Inc..
AstraZeneca.
Myriad Genetics Inc.
Agilent Technologies
Biocept, Inc.
Opko Health, Inc
Mdxhealth
3D Signatures,inc.
Genomic Health
Siemens Healthcare Gmbh
Diasorin S.p.a
Biomerieux SA
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.